Market: KLS |
Currency:
Address:
📈 M&A Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
0-10%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for M&A
No earnings history available for this symbol.
📰 Related News & Research
-
Mary Chia Holdings Limited 9-Month Unaudited Financial Results Ended 31 Dec 2025: No Dividend Declared Amid Ongoing Business Transformation 24
February 12, 2026
Mary Chia Holdings Limited: Financial Review for the Nine Months Ended 31 December 2025 Mary Chia Holdings Limited released its unaudited condensed interim financial statements…
-
Aspen (Group) Holdings Limited 1H FY2026 Results: Revenue Decline, No Dividend Declared Amid Soft Property Market
February 12, 2026
html Aspen (Group) Holdings Limited: 1H FY2026 Financial Analysis & Investment Insight Aspen (Group) Holdings Limited, a Singapore-listed property developer with significant operations in Malaysia,…
-
Mary Chia Holdings Announces Termination of Hong Kong Joint Venture and Full Acquisition of Subsidiary
February 12, 2026
Mary Chia Holdings Limited – Termination of Hong Kong Joint Venture and Share Transfer Mary Chia Holdings Limited Announces Termination of Hong Kong Joint Venture…
-
U.S. Government Awards iX Biopharma $41M Contract to Develop Wafermine® Ketamine Wafer for Military Pain Relief
February 12, 2026
iX Biopharma Secures US\$41 Million U.S. Government Contract for Wafermine® Development iX Biopharma Awarded US\$41 Million U.S. Defense Contract to Advance Wafermine® for Acute Pain…
-
iX Biopharma Awarded US$41 Million U.S. Defense Contract for Development of Non-Opioid Sublingual Ketamine Pain Treatment Wafermine® 1
February 12, 2026
iX Biopharma Awarded US\$41 Million U.S. Government Contract iX Biopharma Secures US\$41 Million U.S. Department of Defense Contract for Non-Opioid Pain Treatment: A Potential Game-Changer…
-
iX Biopharma Announces S$6 Million Share Placement to Fund U.S. Government Contract Execution
February 12, 2026
html iX Biopharma Announces S\$6 Million Placement to Fund U.S. Government Contract iX Biopharma Announces S\$6 Million Placement to Fund U.S. Government Contract Key Points…
-
Toku Secures Major European Enterprise Agreement, Expands AI-Powered Customer Experience Platform Across Europe
February 12, 2026
Toku Secures Multi-Market European Enterprise Agreement with Leading On-Demand Delivery Platform Toku Secures Multi-Market European Enterprise Agreement with Leading On-Demand Delivery Platform Key Highlights and…
-
Beng Kuang Marine FY2025 Corporate Highlights: Asset-Light Turnaround, Financial Resilience, and Offshore Marine Growth
February 12, 2026
Beng Kuang Marine FY2025 Financial Report: Investor Analysis Beng Kuang Marine Limited FY2025 Corporate Highlights: Investor Analysis Key Points and Highlights Resilient Profitability and Financial…
-
Beng Kuang Marine Maintains Profitability in FY2025 Despite Revenue Decline; Proposes Dividend and Strengthens Balance Sheet 14
February 12, 2026
Beng Kuang Marine FY2025 Results: Key Highlights for Investors Beng Kuang Marine Maintains Profitability and Strengthens Balance Sheet in FY2025 Amid Challenging Market Conditions Introduction…
-
TEHO International Announces Deregistration and Striking-Off of Dormant Subsidiaries in 2025
February 12, 2026
TEHO International Inc Ltd. – Corporate Update: Deregistration and Striking-Off of Dormant Subsidiaries TEHO International Inc Ltd. – Corporate Update: Deregistration and Striking-Off of Dormant…
🔍 View more Reports